A. Bellanger, C. F. Donini, J. A. Vendrell, J. Lavaud, I. Machuca-gayet et al., The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone, J. Pathol, vol.242, pp.73-89, 2017.

A. Charehbili, D. B. Fontein, J. R. Kroep, G. J. Liefers, J. S. Mieog et al., Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review, Cancer Treat. Rev, vol.40, pp.86-92, 2014.

Y. H. Chia, M. J. Ellis, and C. X. Ma, Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool, Br. J. Cancer, vol.103, pp.759-764, 2010.

M. Dowsett, I. E. Smith, S. R. Ebbs, J. M. Dixon, A. Skene et al., Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer, J. Natl. Cancer Inst, vol.99, pp.167-170, 2007.

M. Dowsett, I. E. Smith, S. R. Ebbs, J. M. Dixon, A. Skene et al., Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival, Clin. Cancer Res, vol.11, pp.951-958, 2005.

M. J. Ellis, V. J. Suman, J. Hoog, R. Goncalves, S. Sanati et al., Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the american college of surgeons oncology group Z1031 trial (Alliance), 2017.

, J. Clin. Oncol, vol.35, pp.1061-1069

M. J. Ellis, V. J. Suman, J. Hoog, L. Lin, J. Snider et al., Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031, J. Clin. Oncol, vol.29, pp.2342-2349, 2011.

M. J. Ellis, Y. Tao, J. Luo, R. A'hern, D. B. Evans et al., Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics, J. Natl. Cancer Inst, vol.100, pp.1380-1388, 2008.

C. M. Focke, T. Decker, and P. J. Van-diest, Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours, Histopathology, vol.69, pp.849-861, 2016.

B. Gyorffy and R. Schafer, Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients, Breast Cancer Res. Treat, vol.118, pp.433-441, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00535315

T. Iwamoto, T. Katagiri, N. Niikura, Y. Miyoshi, M. Kochi et al., Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers, Oncotarget, vol.8, pp.26122-26128, 2017.

H. Iwata, N. Masuda, Y. Yamamoto, T. Fujisawa, T. Toyama et al., Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study, Breast Cancer Res. Treat, 2018.

M. Marous, I. Bieche, X. Paoletti, M. Alt, A. R. Razak et al., Designs of preoperative biomarkers trials in oncology: a systematic review of the literature, Ann. Oncol, vol.26, pp.2419-2428, 2015.

C. Morigi, Highlights from the 15th St Gallen International Breast Cancer Conference 15, Ecancermedicalscience, vol.11, p.732, 2017.

N. T. Nguyen, J. A. Vendrell, C. Poulard, B. Gyorffy, S. Goddard-leon et al., A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers, Mol. Oncol, vol.8, pp.1441-1457, 2014.

M. Y. Polley, S. C. Leung, D. Gao, M. G. Mastropasqua, L. A. Zabaglo et al., An international study to increase concordance in Ki67 scoring, Mod. Pathol, vol.28, pp.778-786, 2015.

D. L. Rimm, S. C. Leung, L. M. Mcshane, Y. Bai, A. L. Bane et al., An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer, Mod. Pathol, vol.32, pp.59-69, 2018.

H. S. Rugo, N. Vidula, and C. Ma, Improving response to hormone therapy in breast cancer: new targets, new therapeutic options, Am. Soc. Clin. Oncol. Educ. Book, vol.35, 2016.

A. K. Turnbull, L. M. Arthur, L. Renshaw, A. A. Larionov, C. Kay et al., Accurate prediction and validation of response to endocrine therapy in breast cancer, J. Clin. Oncol, vol.33, pp.2270-2278, 2015.

J. A. Vendrell, A. Thollet, N. T. Nguyen, S. E. Ghayad, S. Vinot et al., ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion, Cancer Res, vol.72, pp.3593-3606, 2012.